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ABSTRACT 
Recent research has suggested that the growth of central nervous system 
(CNS) axons during development is mediated through the PI3K/Akt/mammalian 
target of rapamycin (mTOR) intracellular signalling axis and that suppression of 
activity in this pathway occurs during maturity as levels of the phosphatase and 
tensin homolog (PTEN) rise and inhibit PI3K activation of mTOR, accounting for the 
failure of axon regeneration in the injury adult CNS.  This hypothesis is supported by 
findings confirming that suppression of PTEN in experimental adult animals 
promotes impressive axon regeneration in the injured visual and corticospinal motor 
systems.  This review focuses on these recent developments, discussing the 
therapeutic potential of a mTOR-based treatment aimed at promoting functional 
recovery in CNS trauma patients, recognising that to fulfil this ambition, the new 
therapy should aim to promote not only axon regeneration but also remyelination of 
regenerated axons, neuronal survival and re-innervation of denervated targets 
through accurate axonal guidance and synaptogenesis, all with minimal adverse                                         
effects.  The translational challenges presented by the implementation of this new 
axogenic therapy are also discussed. 
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INTRODUCTION 
Recent research aimed at promoting axon regeneration in the injured central 
nervous system (CNS) has achieved impressive regrowth of long axonal tracts by 
activation of the phosphatidylinositol/protein kinase B/mammalian target of 
rapamycin intracellular signalling pathway (PI3K/Akt/mTOR; mTOR is used 
throughout as an inclusive term for mTORC1 and mTORC2 – abbreviations of all 
signalling molecules are given in Fig. 1) (reviewed by Liu et al., 2011; Kanno et al., 
2012; Aruni et al., 2012; Maiese et al., 2013; Maiese, 2014; Lu et al., 2014).  These 
and others studies attribute the poor prognosis for functional restitution to 
suppression, at around birth, of developmental mTOR-mediated neuroprotection and 
axogenic protein synthesis (Park et al., 2008, 2010; He, 2010; Pernet and Schwab, 
2014).  This proposition predicts that treatments which re-establish the sensitivity of 
the PI3K/Akt pathway to growth factor activation in maturity augur well for the 
restoration of function in CNS trauma patients. 
During mammalian CNS development, the viability of neurons and growth of 
axons is supported by neurotrophic factors (NTF) such as: (i), neurotrophins (NT) 
including nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), 
neurotrophic factor 3 (NT3), and NT4/5, which activate the PI3K/Akt intracellular 
signalling pathway after engaging tyrosine kinase receptors (Trk); and (ii), cytokines 
such as ciliary neurotrophic factor (CNTF), interleukin-6 (IL-6) and leukemia 
inhibitory factor (LIF) all of which bind to the trimeric gp130 receptor complex and 
activate PI3K through JAK/SHP2 signalling (Heinrich et al., 2003; Müller et al., 2007, 
2009) - negatively regulated by suppressor of cytokine signalling 3 (SOCS3) 
(Nicholson et al., 2000) (Fig.1).  The PI3K/Akt pathway controls cell survival and 
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axogenic protein synthesis (reviewed by Fonseca et al., 2014) through mTORC1 and 
also cytoskeletal growth cone dynamics by modulation of GSK3β activity (Zhou and 
Snider, 2005; Liu et al., 2012), potentiated through the mTORC2/Akt loop.  CNS 
axon growth declines during maturation, possibly through suppression of NTF 
responsiveness engendered by a progressive up-regulation of the PI3K antagonist, 
phosphatase and tensin homolog (PTEN), a decline in IL-6 secretion by astrocytes 
and neurons (Codeluppi et al., 2014), a rise in the ratio of repressors:enhancers of 
transcriptional axon growth Kruppel-like factors (KLF) (Arlotta et al., 2005; Moore et 
al., 2009), and soaring titres of scar- and myelin-derived axon growth inhibitory 
factors (AGIF), the potency of which is enhanced by a postnatal decline in 
intracellular cAMP (Shewan et al., 2002; Peace and Shewan, 2011;Cai et al., 2001).  
Further suppression of mTOR is induced in mature CNS neurons after axotomy (Liu 
et al., 2010; Park et al., 2010) but pten gene deletion re-activates the PI3K/Akt 
pathway promoting new axon growth and additional NTF/cytokine priming may be 
required to initiate axon sprouting (Leibinger et al., 2012; Fischer and Leibinger, 
2012; Lee et al., 2014). 
Because of the cellular omnipresence of the mTOR pathway, many phenotypes 
in the CNS are affected indiscriminately by mTOR-related treatments unless cell 
targeting techniques are employed.  The cellular functions of mTOR include the 
regulation of metabolism, growth, proliferation and viability (Laplante and Sabatini, 
2009; Dibble and Cantley, 2015) and the uncontrolled dysregulation of any of these 
responses could provoke potentially deleterious side effects in the CNS.  In 
experimental animals, Cre/loxP recombination and delivery of DNA and si/shRNA 
PI3K/Akt/mTOR therapies to neurons is achieved using phenotypic promoters and 
neurotrophic adeno-associated virus (AAV) serotypes with minimal effects on non-
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neuronal cells.  However, although genes may be successfully targeted to particular 
neurons using phenotypic promoters (e.g. Thy1 for RGC), AAV vector neurotropism 
is age-dependent and not absolute (Harvey et al., 2002; Aschauer et al., 2013; 
Gholizadeh et al., 2013) and may lead to potentially deleterious side effects in non-
targeted cells.  Neural targeting of conditional gene deletion has employed local 
injection of specific neurotrophic AAV-Cre constructs into CNS sites where the floxed 
neuronal phenotype is concentrated (e.g. intravitreal injection of AAV2/Cre for floxed 
retinal ganglion cells (RGC)) but does not entirely insure against gene deletion in 
non-neuronal floxed cells and leads to gene knockout in widespread areas of the 
CNS outside the AAV-Cre injection site (Thévenot et al., 2003; Ahmed et al., 2004; 
Madisen et al., 2015; Yang et al., 2015).  Moreover, a therapy that claims to promote 
recovery in CNS trauma patients by targeted activation of the PI3K/Akt/mTOR 
pathway, would need to meet the following criteria: (i), high levels of neuro-protection 
for axotomised neurons; (ii) axon regeneration for all axotomised neurons; (iii), 
accurate axon guidance to the original denervated targets; (iv), homologous 
synaptogenesis within targets; (v), congruent myelination of different calibre 
regenerated axons; (vi), minimal adverse effects; and (vii) translation into the clinic of 
the candidate regimen – a tall order for a uni-dimensional treatment? 
 
NEURO-PROTECTION 
The numbers of neurons surviving axotomy determines the prospective 
number of axons available for regeneration.  However, since mature neurons are not 
mitotic, those lost after injury are not replaced.  Axotomy is often lethal because the 
constant supply of vital NTF, transported retrogradely along axons from innervated 
targets, is discontinued (reviewed by Bähr, 2000; Cellerino et al., 2000); 
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nonetheless, those neurons with axon collaterals preserved proximal to transection 
survive and this probably accounts for the viability of axotomised dorsal root ganglion 
neurons (DRGN) and corticospinal tract neurons (CSTN).  However, because only a 
few RGC have collaterals within the retina, and none have collaterals in the optic 
nerve (ON), RGC are especially sensitive to ON crush (ONC) when, in rats, 50% die 
by 7d post lesion (dpl) and >90% by 14dpl (Berkelaar et al., 1994).  The 10% of RGC 
that survive axotomy are mostly melanopsin 1 (M1) and M4 (equivalent to αRGC – 
Estevez et al., 2012) intrinsically photosensitive (ip) RGC, i.e. >80% and ~25% of M4 
and 70% and 15% of M1 ipRGC survive at 14dpl and 28dpl, respectively (Duan et 
al., 2015).  There are five classes of ipRGC (M1-M5) (Fig. 2), of which M1 and M4 
subtypes comprise ~3% and ~6% of all RGC, respectively.  The properties and 
connections of ipRGC are reviewed by Schmidt et al. (2011), Estevez et al. (2012) 
and Cui et al. (2015).  PTEN promotes cell death by suppressing PI3K signalling and 
activating pro-apoptotic forkhead transcription factors (Nakamura et al., 2000) and 
AMPA type glutamate receptor-mediated excitotoxicity (Liu et al., 2013), but deletion 
of pten does not affect the numbers of M1 and M4 ipRGC (Fig. 2) surviving ONC 
(Duan et al., 2015), although other RGC subtypes are neuro-protected, i.e., ~42.5% 
survive after pten deletion (Park et al., 2008), increased to ~60% after co-deletion of 
pten and socs3 (Sun et al., 2011).  RGC death after ONC correlates with rising 
REDD2/RT801 activity (Fig. 1) and plummeting mTORC1 levels; whereas 
REDD2/RTP801 deletion restores mTORC1 activity and rescues RGC from death 
(Morquette et al., 2014, Morgan Warren et al., 2015), although it has been suggested 
that Akt/GSK3β rather than Akt/mTORC1 signalling may be more important for RGC 
neuro-protection (Chin et al., 2005).  M1 ipRGC spontaneous survival is correlated 
with the existence of axon collaterals within the retina, resistance to glutamate 
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toxicity and possible neuro-protection mediated by melanopsin photo-transduction 
(reviewed by Cui et al., 2015); similar characteristics may prevail for M4 ipRGC 
which also constitutively express pS6 (Duan et al., 2015).  The latter indicates 
endogenously active mTORC1 in these cells (Duan et al., 2015) capable of 
mediating neuro-protection by autophagic degradation and clearance of both 
damaged organelles and abnormal protein aggregates (Chen et al., 2013; Dunlop 
and Tee, 2014; Heras-Sandoval et al., 2014), and also by suppression of caspase 
(CASP) activation (Hanada et al., 2004). 
Inhibition of both CASP2 by siRNA, and by dominant negative knock-down, 
neuro-protects >95% RGC at 14d after ONC (Ahmed et al., 2011; Vigneswara et al., 
2014) (Fig. 3).  To sustain neuronal viability after axotomy, pharmacological neuro-
protection is required for the duration of a regenerative response until target re-
innervation re-instates the target-derived NTF supply.  Although the effects of CASP 
knockdown on M1 and M4 ipRGC are unknown, direct CASP2 suppression 
promotes better pan-RGC survival than pten deletion, implying that an anti-CASP2-
based anti-apoptotic therapy may be the optimal pan-RGC neuro-protective 
treatment.  Combining mTOR with stem cell therapy may offer an alternative strategy 
for increasing neuron numbers after trauma by either replacing lost neurons, 
providing NTF support for surviving axotomised neurons, or promoting the release of 
stem cell-derived neuron-differentiating growth factors (reviewed Mead et al., 2015).  
For example, after spinal cord injury, mTOR-dependent differentiation of 
transplanted neural stem cells into glia and neurons and the subsequent growth of 
axons establishes functional connections above and below the lesion (Lu et al., 
2014; Peru et al., 2008). 
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AXOGENESIS 
The reliance of regenerating axons on PI3K/Akt/mTOR activation may vary 
across the spectrum of neuronal phenotypes and even within the axon trajectories of 
a single neuron (Lee et al., 2014).  A small population (~10%) of RGC regenerate 
axons after NTF/cytokine administration (Berry et al., 1996; 1999; Pernet et al., 
2013b) and knockdown of pten (Park et al., 2008; Sun et al., 2011; de Lima et al., 
2012a, b; Kurimoto et al., 2010) (Fig. 4A, B).  Paucity in number is explained by the 
finding that RGC axon regeneration is exclusively restricted to M4 ipRGC (Fig. 4C) 
that have high titres of constitutively active mTORC1 (i.e. are pS6+), express 
osteopontin and insulin-like growth factor receptor (IGFR) (Duan et al., 2015) and 
project to the dorsal lateral geniculate nucleus (DLGN) (Estevez et al., 2012; Brown 
et al., 2010; Ecker et al., 2010; Schmidt et al., 2014), although the full extent of their 
innervation fields is yet to be defined.  Interestingly, similar numbers of M4 ipRGC 
axons regenerate after osteopontin plus IGF-1 treatment as after pten deletion, 
indicating that both regulate PI3K/Akt axogenic activity in M4 ipRGC.  Paradoxically 
however, although osteopontin and IGF expression is induced in reactive Müller glia 
and microglia after ONC by ischaemic and excitotoxic retinal injury and by glia 
derived neurotrophic factor (GDNF) administration (Kermer et al., 2000; Morimoto et 
al., 2005; Chidlow et al., 2008; Del Rio et al., 2011), RGC axons do not regenerate in 
these paradigms.  Many ipRGC connect with multiple brain centres outside the visual 
thalamus and subserve the non-image-forming visual functions of circadian photo-
entrainment (suprachiasmatic nucleus – SCN and intergeniculate leaflet - IGL), 
pupillary reflexes (olivary pretectal nucleus – OPN), visual masking (ventral sub-
paraventricular zone - VSPZ) and sleep patterns (ventrolateral preoptic nucleus – 
VLPON) (Estevez et al., 2012; Hattar et al., 2006; Schmidt et al, 2011; Duan et al., 
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2015; Cui et al., 2015) but M4 ipRGC driven by rod and cone bipolar cell inputs may 
also contribute to pattern vision through their DLGN projections (Estevez et al., 
2012).  Consistently, <10% RGC axons regenerate irrespective of either the 
axogenic or neuro-protective stimuli employed (reviewed by Berry et al., 2008).  The 
explanation for restricted RGC axon regeneration may rest with the observation that 
only M4 axons regenerate after mTORC1 activation (Duan et al., 2015) and thus 
increasing the survival of other RGC subsets would not improve axon regenerative 
success; an observation that forecasts limited recovery of sight in blind patients after 
pten deletion, since rod/cone-mediated conscious perception of pattern colour vision 
may not be restored (Cui et al., 2015). 
It is not known if a similar diversity in growth factor requirements and limited 
mTORC1-mediated neuro-protection seen in RGC (Duan et al., 2015) applies to 
other groups of neurons, e.g. DRGN and CSTN.  Rheb activation of mTOR (Fig. 1) 
combined with a chondroitinase ABC anti-scarring treatment promotes CST axon 
regeneration in the injured cord (Wu et al., 2015).  However, after pten deletion by 
AAV-Cre injection of the motor cortex of floxed adult mice, CSTN axons regenerate 
through acute spinal cord lesions (Fig. 4D) (Liu et al., 2010; Zukor et al., 2013) and 
surprisingly also through chronic lesions after AAV-Cre cortical injections are 
delayed by 1 month and 1 year after injury (Du et al., 2015) without supplementation 
with an anti-fibrotic regime.  These latter findings indicate that acute and chronic scar 
tissue does not impede the transit of regenerating axons through a CNS lesion and 
that neurons have an extended axogenic potential after axotomy – good news for 
chronic spinal patients.  The peripheral (Abe et al., 2010; Christie et al., 2010) but 
probably not central projections of DRGN also regenerate after pten deletion.  
However, spontaneous sprouting of spared CSTN axons after pyramidotomy is 
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independent of mTOR activation (Lee et al., 2014), while pten and nogo (a CNS 
myelin-derived agil gene) co-deletion enhances CSTN axon regeneration but not 
sprouting (Geoffroy et al., 2015), supporting the contention that mTOR regulates 
axon elongation rather than the initiation of axon growth (Leibinger et al., 2012; 
Fischer and Leibinger, 2012, Morgan-Warren et al., 2015).  PI3K/Akt stimulated 
peripheral axon regeneration is insensitive to rapamycin, as is DRGN neurite 
outgrowth (Christie et al., 2010), suggesting that growth of both central and 
peripheral DRGN projections is not mediated by the Akt/mTORC1 but by the 
Akt/GSK3β pathway enhanced by mTORC2/Akt activity (Fig. 1) – although this 
assertion is controversial since DRGN axon/neurite outgrowth has been reported 
after both GSK3β inhibition and activation (Zhou et al., 2004; Dill et al., 2008; 
Saijilafu et al., 2013, Gobrecht et al., 2014).  Even so, the possible failure of large 
phenotypic groups of axotomised neurons to regenerate their axons after mTOR 
treatment could give rise to neurological sequelae that exacerbate the already poor 
quality of life of CNS injured patients.  For example, the demonstration that CSTN 
and DRGN have differential sensitivities to mTOR predicts that, although paraplegic 
patients may become ambulatory after mTOR activation, they will be left with 
anaesthesia, paraesthesia, neuralgia and without proprioception (as a consequence 
of failed dorsal column/spinothalamic/spinocerebellar tract regeneration), possibly 
equivalent to the sensory deprivation and dyskinesia seen in tabes dorsalis. 
 
AXON GUIDANCE 
Axon regeneration alone will not re-establish useful function without 
restoration of the original topographically organised connections.  In the adult 
mammalian CNS, re-innervation of former targets is a poorly executed rare event 
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(Luo et al., 2013; Diekmann et al., 2013).  In the visual system, only M4 ipRGC 
axons regenerate after pten deletion (Duan et al., 2015) and appear to establish 
homologous connections in the contralateral DLGN (Kurimoto et al., 2010; de Lima 
et al., 2012a, b), other presumptive M4 axons project ectopically into the 
hypothalamus (characteristic of M1 ipRGC projections, which do not regenerate), 
ipsilateral optic tract, and centrifugally within the ipsilateral and contralateral ON (Luo 
et al., 2013; Yungher et al., 2015) (Fig. 5).  Similar aberrant RGC trajectories of 
presumptive M4 ipRGC axons may occur after NTF/cytokine stimulation and 
inflammation, independent of targeted up-regulation of mTOR (Berry et al., 1999; 
Pernet et al., 2013a, b) and could be mediated by osteopontin/IGF released from 
reactive Müller cells, retinal astrocytes and microglia (Kermer et al., 2000; Morimoto 
et al., 2005; Chidlow et al., 2008). 
Ontogenetic guidance of axon growth and disinhibition of adult regenerating 
axons in the CNS have much in common; they both exploit growth cone collapse and 
some developmental repellent guidance ligands are also axon growth inhibitory 
ligands (AGIL) in the mature CNS (e.g. Sema 3A).  In the adult, AGIL derived from 
incipient scar tissue and from myelin (reviewed by Sandvig et al., 2004), bind to their 
cognate receptors and activate signalling pathways which converge on RhoA and 
mediate growth cone collapse by depolymerisation of actin/microtubule filaments 
through the ROCK/LIMK/Cofilin pathway (reviewed by Ahmed et al., 2005).  For 
instance, myelin-derived AGIL bind to the Nogo receptor (NgR) complex comprised 
of AGIL-binding, membrane anchored, extracellular NgR, Lingo/Amigo co-receptors 
and transmembrane signalling p75NTR/TROY components.  It was quickly realised 
that axons blinded to AGIL after knock-down of either NgR (Zheng et al., 2003), 
RhoA or ROCK (Ichikawa et al., 2008; Lingor et al, 2007, 2008; Ahmed et al., 2009) 
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will not regenerate unless growth cone advance is also stimulated by NTF/cytokines 
(Ahmed et al., 2005, 2009) and intracellular axogenic pathways are activated (Liu et 
al., 2011; Geoffroy and Zheng, 2014).  Additionally, the discovery that NTF (including 
a combination of CNTF/BDNF/NT-3/FGF-2) induce regulated intramembranous 
proteolysis (RIP) of the p75NTR signalling NgR co-receptor (Ahmed et al., 2005; 
2006, 2009) revealed the axiom that the coupling of axogenesis with growth 
disinhibition is mandatory for NTF-induced axogenesis in the AGIL-rich adult CNS. 
Binding of Sema 3 family of axon guidance molecules to the neuropilin/plexin 
receptor complex inhibits PI3K/Akt signalling disrupting mTOR1/2 dependent 
activation of RhoA (Nakayama et al., 2015).  Axon trajectories may also become 
disordered when PI3K/Akt activation inhibits ephrin-induced growth cone collapse 
after disturbed Rheb signalling in tsc2 haplo-insufficiency mice (Nie et al., 2010), and 
to altered growth cone sensitivity to AGIL/axon guidance cues after moderation of 
GSK3β signalling (Dent and Gertler, 2003; Zhou and Snider, 2005).  GSK3β controls 
axon outgrowth de novo, guidance and branching by regulating multiple 
transcriptional factors and also growth cone actin filament/microtubule assembly 
through cytoskeletal binding proteins, including collapsing response mediator protein 
(CRMP) and adenomatous polyposis coli (APC) (Fig.1) in response to 
inhibition/attraction guidance ligands (reviewed by Dent and Gertler, 2003; Goold et 
al., 2004; Zhou and Snider, 2005; Hur and Zhou, 2010; Liu et al., 2012).  GSK3β is 
constitutively active and either inhibited by Akt phosphorylation (Arevalo and 
Rodriguez-Tébar, 2006; Dill et al., 2008) or activated by repulsive guidance cues and 
AGIL (Zhou and Snider, 2005; Ito et al., 2006; Shen et al., 2011; Eickholt et al., 
2002).  However, the finding that inhibition of GSK3β can also block axon growth 
(Alabed et al., 2010) has led to the concept that differential priming of substrates by 
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phosphorylation determines whether GSK3β promotes the advance or collapse of 
growth cones (Kim et al., 2006).  Activated GSK3β regulates the sequential 
phosphorylation of cyclin-dependent kinase 5 (Cdk5) as well as both primed CRMP 
(Uchida et al., 2005) and APC (Zumbrunn et al., 2001), causing growth cone 
collapse by abrogating binding to the cytoskeleton (Fukata et al., 2002).  By inhibiting 
GSK3β, the PI3K/Akt axogenic pathway acts to disinhibit by default AGIL-mediated 
inhibition of axon growth (Uchida et al., 2005; Zhou et al., 2005).  Accordingly, CST 
and serotonergic axons regenerate in the injured cord after lithium-induced inhibition 
of GSK3β (Dill et al., 2008), DRGN axons regenerate through AGIL-rich dorsal 
column glial scars after GSK3β-deletion (Liz et al., 2014) and the neurites of cortical 
neurons grow on an AGIL-coated substrate after over-expression of phospho-Akt 
and deletion or knockdown of pten (Perdigoto et al., 2011).  Growing axons are 
steered through CNS neuropil by collapse and counter-collapse in different regions 
of their growth cones and thus AGIL/repulsion guidance cue-activation of GSK3β 
may not completely arrest axon growth (Zhou et al., 2004; Hur et al., 2010).  Hence, 
assuming that ontogenetic path finding maps are retained in mature CNS neuropil 
(discussed by Koeberle and Bähr, 2004), misguidance of regenerated adult axons 
after pten deletion, shRNA pten silencing (Yungher et al., 2015) and activation of the 
PI3K/Akt pathway may be attributed to an inability of growth cones to respond to 
AGIL and repellent guidance cues that define the boundaries of the original axon 
trajectories, implying that CNS axogenic treatments are incompatible with functional 
recovery, since NTF-induced RIP- and GSK3β-mediated disinhibition (essential for 
growth cone advance in the mature CNS) inevitably fashions disorganised 
connectivity.  This disinhibited axon growth paradox may become an impediment for 
researchers attempting to achieve functional recovery after CNS injury, although the 
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preservation of axon fasciculation mechanisms may compensate for poor path 
finding when attraction/repulsion cues are not detected (Marcos et al., 2015). 
 
SYNAPTOGENESIS 
Connectivity is controlled by mTOR-mediated regulation of dendritic stability 
(Morquette et al., 2014), synaptic protein production, synaptic plasticity (Hoeffer and 
Klann, 2009) and the morphology and possibly the density of dendritic spines (Lai et 
al., 2006; Li et al., 2010; Haws et al., 2014; Di Polo, 2015).  After spinal cord injury, 
pten deletion stimulates transected CST axons to regrow through the lesion (Fig. 4D) 
and form new synapses in homotopic regions of the caudal cord, suggesting re-
engagement of former post-synaptic membranes (Liu et al., 2010; Zukor et al., 
2013).  In the visual system after pten/socs3 co-deletion, new synaptic connections 
are formed in the SCN by regenerating axons (Li et al., 2014, Yungher et al., 2015), 
presumed to be heterotopic contacts of misguided regenerating M4 ipRGC axons 
since, after pten deletion/silencing, MI ipRGC axons (that normally innervate the 
SCN) do not regenerate (Duan et al., 2015).  In adult mice after pten deletion 
combined with cAMP and zymogen administration, homotopic DLGN and SC re-
innervation by presumptive regenerating M4 ipRGC axons may explain the partial 
return of both depth perception and visually guided behaviours (de Lima et al., 
2012a, b), but the return of circadian photo-entrainment, normally mediated by M1-
SCN connections (Estevez et al., 2012; Hattar et al., 2006; Schmidt et al, 2011; 
Duan et al., 2015), is unexpected and more difficult to explain.  Thus, aberrations in 
axon guidance (see above) together with ectopic synaptogenesis after pten deletion 
may cause gross CNS dysfunction (Ebrahimi-Fakhari and Sahin, 2015), although the 
capacity of the CNS to preferentially process information from the original, 
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denervated centres after suboptimal re-innervation, while filtering out misinformation 
generated in rogue connections, may restore limited function after activation of 
mTOR (Weidner et al., 2001).  However, in CNS with raised mTOR activity, 
imbalance in excitatory and inhibitory synaptic activity and disordered transmission 
of action potentials through abnormally myelinated regenerated neural circuits are all 
likely to cause seizures and deterioration in intellect, memory and cognition (Garcia-
Junco-Clemente and Golshani, 2014; Williams et al., 2015). 
 
MYELINATION OF REGENERATED AXONS 
Return of function after CNS injury is critically reliant on remyelination of 
regenerated axons to re-instate the temporal integrity of axon conduction patterns 
between centres and to preserve the viability of axons (reviewed by Doring and 
Yong, 2011; Franklin et al., 2012).  The prevalence of psychiatric and neurological 
conditions in myelin disorders, including the Tuberous Sclerosis Complex (TSC) 
genetic disorder, is probably explained by such desynchronisation of propagated 
axon potentials caused by changes in conduction velocities and refractory times as a 
consequence of abnormal ‘g’ ratios (diameters of axon:myelinated fibre), variable 
inter-nodal lengths and abnormal nodal physiology (Fields, 2008; Bartzokis, 2012).  
Schwann cells invade penetrant lesions of the CNS, myelinate axons and often 
become replaced by remyelinating oligodendrocyte precursors (OPC – reviewed by 
Crawford et al., 2014) and oligodendrocytes (Jasmin and Ohara, 2002).  A few 
regenerating axons in the transected ON become myelinated after pten deletion (de 
Lima et al., 2012a, b), but whether by oligodendrocytes or Schwann cells is 
unknown.  In demyelinating diseases, like multiple sclerosis, remyelination is limited, 
transient and often fails, probably because of impaired recruitment of OPC and their 
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failure to both make contact with axons and differentiate into myelinating 
oligodendrocytes (Flores et al., 2000; Chari, 2007; Franklin and Kotter, 2008; 
Franklin and ffrench-Constant, 2008; Barros et al., 2009; Tyler et al., 2009; Bruce et 
al., 2010; Patel and Klein, 2011).  In addition, CNS remyelination efficiency wanes 
with age as OPC differentiation potential decreases (reviewed by Franklin and 
ffrench-Constant, 2008) and the frequency of type-M2 microglia declines, suggesting 
a pro-remyelinating influence of type–M2 microglia on OPC differentiation (Miron et 
al., 2013).  Regenerated axons in the adult CNS may also have defective myelin with 
related dysfunctional outcomes, because remyelination of regenerated axons is likely 
to be as aberrant as that of axons demyelinated by disease.  Oligodendrocyte 
myelination is principally regulated by mTORC1 and the PI3K/AKT/GSK3β pathway 
(Tyler et al., 2009; Narayanan et al., 2009; Azim and Butt, 2011; Normén and Suter, 
2013; Dai et al., 2014; Wood et al., 2013; Lebrun-Julien et al., 2014; Wahl et al., 
2014; Bercury et al., 2014; reviewed by Bartzokis, 2011), whereas mTORC2 has a 
modest effect on differentiation with little influence on myelination (Bercury et al., 
2014), but the roles of these signalling molecules in remyelination are contentious.  
Myelin gene transcription is down regulated (Lai et al., 2006) and myelination is 
retarded (Sachs et al., 2014) after suppression of mTORC1, either by deletion of Akt 
or treatment with rapamycin, whereas over active mTORC1 promotes remyelination 
and improves conduction and refractoriness (Moore et al., 2014).  Moreover, 
oestrogen receptor (ER) α and β ligand-activation of PI3K/Akt in oligodendrocytes 
co-activates Trk and IGF receptors and potentiates IGF1-induced OPC proliferation 
(Kumar et al., 2013), inhibition of PTEN promotes MBP accumulation and stimulates 
myelination (De Paula et al., 2014) and over expression of phospho-Akt increases 
myelin protein production leading to hyper-myelination (Goebbles et al., 2010).  
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Counter-intuitively however, mTOR activation can cause defective oligodendrocyte 
differentiation after deletion of Rheb1 (Fig. 1) in murine neural progenitor cells (Zou 
et al., 2004).  GSK3β also has contradictory effects, inducing both hyper-myelination 
(Carson et al., 1993; Freude et al., 2008) after inhibition by either Akt (Flores et al., 
2008; Narayanan et al., 2009; Goebbles et al., 2010; Yu et al., 2011) or IGF (Fig. 1) 
and oligodendrocyte formation and remyelination through the regulation of Wnt-β-
catenin, Notch and CREB signalling (Azim and Butt, 2011).  Hyper-myelination 
induced by mTOR over activity in the mouse ON is correlated acutely with short 
latencies of visually evoked potentials, which later become delayed as myelin 
sheaths thicken and decompact (Yu et al., 2011).  Although precise unequivocal 
neuronal targeting of mTOR therapies would protect against possible adverse hyper-
myelination effects (Lai et al., 2006; Goebbles et al., 2010; Zou et al., 2011; De 
Paula et al., 2014), re-myelination of regenerated axons would require a 
supplementary OPC-oligodendrocyte differentiation regimen (not yet available - 
Doring and Yong, 2011) to restore normal conduction in regenerated axons. 
 
ADVERSE EFFECTS OF mTOR HYPERACTIVITY IN THE CNS 
The use of rapamycin and its analogues as immunosuppressive, anti-cancer, 
pro/anti-inflammatory and anti-angiogenic agents emphasises the potential for 
activated mTOR to cause severe pathologies in the CNS.  Indeed, the control by 
mTOR of cell proliferation and growth, food intake and stress reactions makes it 
unsurprising that over activity is linked to cancer, diabetes, obesity and 
cardiovascular and neurological conditions.  The latter include Huntington’s, 
Alzheimer’s, Parkinson’s and TSC diseases in which autism, a decline in intellectual 
and cognitive function, epilepsy, abnormal protein translation and nerve growth are 
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all prevalent (Inoki et al., 2005; Lai et al., 2006; Tsang et al., 2007; Yang and Guan, 
2007; Chong et al., 2010; Don and Zheng, 2011; Don et al., 2012; Alayev and Holz, 
2013; O’Neill, 2013).  Such adverse side effects of mTOR activation are expected to 
be largely eliminated in prospective axogenic therapies employing fail-safe neuronal 
targeting.  Nonetheless, in response to perturbed mTORC1 signalling, which 
frequently occurs during tumour formation and associated angiogenesis, targeted 
pharmacological suppression of mTORC1, PI3K, Akt and TSC1/2 (Fig. 1) are 
emerging as effective treatments for multiple forms of cancer (Hay, 2005; Yang and 
Guan, 2007; Don et al., 2012; Alayev and Holz, 2013; Cargnello et al., 2015), contra-
indicating mTOR-based axogenic therapies for CNS trauma patients, particularly 
those with a high risk of cancer.  Moreover, elevated mTORC1 activity after Akt 
hyperactivity, pten deletion, suppression of both PTEN (Hay, 2005; Alayev and Holz, 
2013) and TSC1/2 (Crino et al., 2006; Sosunov et al., 2008) (Fig.1) all promote the 
growth of benign and malignant glia tumours, including the transformation of OPC 
into malignant glioma (Galvao et al., 2015; Duzgun et al., 2015), accompanied by an 
astrocytosis (Li et al., 1997, 2015; Fraser et al., 2004; Wullschleger et al., 2006; 
Codeluppi et al., 2009, 2014; Latacz et al., 2015).  The net effect of the latter may 
also be functionally detrimental, arresting axon growth and generating epileptic foci 
in the injured CNS, since reactive astrocytes: (i), are a rich source of the AGIL, 
inhibiting both axon regeneration and synaptogenesis (Sandvig et al., 2004; Li et al., 
1997; Fraser et al., 2004; Silver and Miller, 2004; Wullschleger et al., 2006, Liu et al., 
2006; Codeluppi et al., 2009; Sofroniew, 2009); and (ii), have impaired glutamate 
uptake leading to seizures as increasing titres of extracellular glutamate accumulate 
(Ulmann et al., 2002; Wong et al., 2003).  Despite all the above and the predilection 
of pten+/- mice to develop multiple neoplasias (reviewed by Hay, 2005), no tumours 
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have been observed in the CNS after neuron-targeted pten deletion in short duration 
axon regeneration studies in which non-neuronal cells may also be affected, 
although long term outcomes have yet to be evaluated (Ali et al., 1999).  
Nevertheless, until the above high carcinogenic risks and unreliability of neuronal 
targeting are eliminated, potentially carcinogenic mTOR-related therapies are 
unlikely to achieve clinical approval. Recent unbiased high-throughput functional 
screening of the genome for phosphatase suppressors of axon regeneration has 
identified an axogenic pathway independent of the PI3K/Akt/mTOR pathway opening 
up the prospect of development of axogenic gene therapies which knock-out non-
pten phosphatases (Zou et al., 2015). 
 
TRANSLATABLE mTOR-BASED THERAPIES 
Many of the gene therapy techniques used in experimental animals to achieve 
activation of mTOR and axon regeneration (e.g., Flox/loxP recombinant inducible 
gene deletion of pten) are not translatable possibly because of ethical, toxicity and 
anti-mitotic issues compounded by the development of cavitation lesions and 
chromosomal aberrations (e.g. Pfeifer et al., 2001; Loonstra et al., 2001; Schmidt et 
al., 2000).  Refinements in the clinical use of chemically modified synthetic si/shRNA 
for knock-down of specific genes (e.g. siRTP801, which has undergone a Pfizer 
Phase II clinical trial for the treatment of wet age-related macular degeneration 
(AMD) (DDIT4, Quark Pharmaceuticals/Pfizer, Ness Ziona, Israel) have eradicated 
the problems of incomplete transient non-specific gene silencing, innate immune 
responses, instability, degradation and the need for multiple injections (Ahmed et al., 
2011; Guzman-Aranguez et al., 2013).  Combinations of AAV-
shPTEN+CNTF+cAMP promote enhanced RGC axon regeneration, compared to 
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pten deletion alone, with extensive re-innervation of central targets (Yungher et al., 
2015), although the caveats relating to poor axon guidance and aberrant target re-
innervation apply (see above).  Thus, a chemically modified synthetic si/shRNA 
could be developed for use in the clinic as an alternative to pten deletion, although 
specific unequivocal RGC targeting may not be achievable (Ahmed et al., 2011).  For 
example, intravitreal injections of siRTP801 raise mTOR activity in the retina and 
induce bystander effects in Müller glia and astrocytes which are partially responsible 
for the resulting RGC survival and limited axogenesis (Morgan-Warren et al., 2015).  
Treatments which target elements located higher up-stream in the PI3K/mTOR 
pathway may cause numerous undesirable down-stream side effects, and more 
distal down-stream targeting of, for instance, TSC1/2, mTORC1, GSK3β and 
CRMP/APC reduce but do not eradicate these risks because focal points of 
activation of alternative regulatory pathways exist, even at these levels.  Small 
molecule kinase inhibitors could qualify as translatable drug candidates but often 
have a high incidence of unwanted off-target side effects, as well as toxicity, 
absorption, distribution, metabolism and excretion issues (Meijer et al., 2004; 
Rosivatz et al., 2006; Douglas et al., 2009).  NTF therapies also have a chequered 
history of success in both laboratory animal (Harvey et al., 2012) and clinical studies 
(Thoenen and Sendtner, 2002), but the discovery that subtypes within phenotypic 
groups of neurons may require particular combinations of growth factors to stimulate 
axon regeneration (Duan et al., 2015) suggests that such therapies may ultimately 
evolve as cocktails of multiple factors capable of promoting axon regeneration in all 
axotomised subtypes.  However, after spinal cord injury, multiple neuronal subsets 
become axotomised and thus a plethora of growth factor combinations may be 
required to promote the regeneration of all transected ascending, descending and 
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intra-spinal tracts, possibly making growth factor treatment impracticable.  Moreover, 
since NTF induce RIP of the p75NTR signalling component of NGR, the disinhibited 
axon growth paradox complicates the development of growth factor based 
treatments for CNS axon regeneration. 
 
CONCLUSIONS 
The mTOR antagonist rapamycin and its analogues are used to treat cancer 
and thus the intention to develop a therapy which elevates mTORC1 activity would 
constitute an anathema to oncologists.  Neural targeting might eradicate the 
carcinogenic risks (since mature neurons rarely, if ever become malignant), but 
would force the design of a combinatorial therapy to promote, in addition to 
axogenesis, oligodendrocyte myelination of regenerated axons and more 
comprehensive viability of axotomised neurons using an anti-CASP regimen.  
However, neural targeting of mTOR-based therapies does not eliminate the 
problems of either limited responsiveness within specific phenotypic neuronal 
groupings or the generation of anomalous axon guidance and synaptogenesis 
through the disinhibited axon growth paradox.  Thus, therapeutic elevation of mTOR 
activity is unlikely to improve and could possibly lead to deterioration in the quality of 
life of CNS injury patients.  Even so, the demonstration in experimental animals of 
long tract axon regeneration after PI3K/Akt activation (Park et al., 2008; Liu et al., 
2010; Kurimoto et al., 2010; Sun et al., 2011), growth factor administration (Berry et 
al., 1999; Pernet et al., 2013b; Duan et al., 2015) and inflammation (Leon et al., 
2000; Fischer, 20210) demonstrates that CNS axon regeneration is feasible clinically 
and not an inherent impossibility as once thought, but a therapy to restore function in 
CNS injury patients is yet to be realised. 
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Figure 1.  Activators of the mTOR axogenic pathway.  Tyrosine receptor kinase (Trk) 
receptors bind neurotrophic factors (NTF) including nerve growth factor (NGF)/brain-
derived neurotrophic factor (BDNF)/neurotrophin 3/4 (NT3/4) which in turn activate 
the Trk/PI3K/Akt pathway; hypoxia, DNA damage and stress activate the 
HIF/RTP801/TSC pathway down stream of Akt; and the gp130 receptor complex 
binds the cytokines leukaemia inhibitory factor (LIF), interleukin 6 (IL6) and ciliary 
neurotrophic factor (CNTF), and activates the janus kinase (JAK)/signal transducers 
and activators of transcription (STAT), cAMP and RAS/CREB pathways (Akt - 
serine/threonine kinase; APC - adenomatous polyposis coli microtubule plus-end–
binding protein; CREB - cAMP response element binding protein; CRMP - collapsin 
response mediator protein; elF4E - eukaryotic initiation factor 4E; 4E-BP1 - eIF4E 
binding to protein 1; Epac - exchange protein directly activated by cyclic adosine 
mono-phosphate (cAMP); ERK - extracellular signal-regulated kinase; GSK3β - 
glycogen synthase kinase 3β; HIFα - hypoxia inducible factor alpha; IGF- insulin-like 
growth factor; IGFR-IGF receptor; IRS1-insulin receptor substrate 1; MAPK - 
mitogen-activated protein kinase; MEK - MAPK/ERK kinase; mTORC1 - mTOR 
(mammalian target of rapamycin)+Raptor (regulatory association protein to 
mTOR)+GβL-G (protein β-subunit-like protein); mTORC2 - mTOR+Rictor (rapamycin 
independent companion of mTOR)+GβL+Sin1; PDK1/2 - phosphatidylinositol-
dependent kinase 1/2; PI3K - phosphatidylinositol 3-kinase; PIP2 - 
phosphatidylinositol (3, 4) bisphosphate; PIP3 - phosphatidylinositol (3, 4, 5) 
trisphosphate; PKA - protein kinase A; SHP-2, a Src homology 2 (SH2) domain 
containing non-transmembrane PTP; PTEN - phosphatase and tensin homolog; RAF 
- proto-oncogene serine/threonine-protein kinases; REDD/RTP801 - regulated in 
development and DNA damage response protein; RAS - rat sarcoma protein; RHEB 
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- Ras homolog enriched in brain protein; RSK - 40S ribosomal protein S6 kinase; 
S6K1 - p70 ribosomal protein S6 kinase 1; S6 - ribosomal protein S6; S727 - 
phosphostat3 serine 727;; SOCS3 - suppressor of cytokine signalling 3; TSCI/2 - 
tuberous sclerosis complex 1/2; Y705 - phosphostat3 tyrosine727). 
 
Figure 2.  Morphology of five types of intrinsically photosensitive retinal ganglion cell 
(ipRGC); (A) en face view of ipRGC dendritic fields (scale bar=100µm), (B) dendritic 
stratification as viewed in a schematic radial retinal section.  Pale blue bands in the 
inner plexiform layer (IPL) are the ON and OFF cholinergic bands.  There are two 
bands of melanopsin dendrites ramifying outside the ON/OFF cholinergic bands; the 
outer lying at the margin of the inner nuclear layer (INL) contains M1 and M3 cell 
dendrites and the inner broader band is juxtaposed to the ganglion cell layer (GLC) 
and contains the dendrites of M2, M3, M4, and M5 cells with subtle differences in 
stratification.  (from ‘Intrinsically photosensitive retinal ganglion cells’, Berson DM, 
reprinted courtesy of The MIT Press from The New Visual Neurosciences edited by 
John S.  Werner and Leo M. Chalupa, with permission). 
 
Figure 3.  Comparison of (A) CASP2 and (B) combined pten/socs3 deletion on the 
survival of axotomised RGC after intra-orbital ONC in rats and mice, respectively.  A.  
Frequencies of FluoroGold back filled rat RGC at 7d post ONC after intravitreal 
injection of a control siRNA targeting a random combination of Caspase nucleotides 
(siCNL) and after escalating doses of siCASP2 at 0d.  Treatment with siCNL resulted 
in 60% RGC survival compared with intact controls, while increasing doses of 
siCASP2 enhanced RGC survival and, over an optimal dose range of 20–35 mg, 
promoted 100% RGC protection compared with intact controls (P>0.001*; from 
Ahmed et al., 2011 with permission).  B.  Synergistic effects on TUJ1+ mouse RGC 
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survival at 4w post ONC and after deletion of pten and socs3.  Percentages of TUJ1+ 
RGC in wild type (WT), pten deleted (PTEN+), socs3 deleted (SOCS3+), and 
combined pten/socs3 deleted (PTEN+/SOCS3+) groups, compared with intact retinae 
(*P>0.001; from Sun et al., 2011 with permission). 
 
Figure 4.  A.  GAP-43+ axons in the non-regenerating and regenerating adult rat ON 
20d after ON transaction; (i), non-regenerating ON in which the growth of GAP43+ 
RGC axons  is arrested in the proximal lesion (*) margin; (ii), after an intravitreal 
sciatic nerve implant at 0d regenerating GAP43+ RGC axons traverse the lesion (*) 
and invade the distal ON segment (note there are more GAP43+ axons in the 
proximal regenerating (ii), compared to the non-regenerating ON (i) because more 
RGC survive in the former; eye to the left, chiasm to the right; magnification bar = 
100μm; from Berry et al., 2008 with permission).  B.  Confocal images of the 
transected adult mouse optic nerve after pten deletion showing regenerated Cholera 
Toxin-B+ (CTB+) axons passing through the lesion site at 14d (i) and 28d (ii) and 
invading the distal optic nerve segment (scale bar = 100mm; the normal response to 
optic crush is essentially similar to that of the rat see A(i) above – from Park et al., 
2008 with permission).  C.  Selective regeneration of M4 ipRGC (αRGC – KCNG4) 
axons in the optic nerves of mice after ONC: (i), CTB anterograde axon tracing 
detects all regenerating RGC axons; (ii), in Kcng4-yellow fluorescent protein (YFP) 
mice YFP+ regenerating axons are exclusively M4 ipRGC axons; (iii), the near 
complete convergence of the images of YFP+ and CTB+ regenerating axons 
demonstrates that most axons derive from M4 (scale bar = 200µm; from Duan et al., 
2015 with permission); ipRGC.  D.  Biotinylated dextran amine+ (BDA+ - red) 
regenerating CST axons on the left side of the cord extending for up to 3mm caudal 
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to the lesion site (*) after pten deletion (longitudinal parasagittal sections of the adult 
mouse spinal cord crushed at the vertebral level of T8).  In these experiments, AAV-
Cre was injected into the right hind limb sensorimotor cortex of PtenloxP/loxP mice 
aged 4w; 4w later the cord was lesioned and, after a further 4w, BDA was injected 
into the right sensorimotor cortex and the mice killed 2w later (scale bar = 500μm; 
from Liu et al., 2010 with permission). 
 
Figure 5. Trajectories of (A) normal RGC axons in a hypothetical representative 
oblique coronal section through the rodent diencephalon (optic nerve (ON); optic 
chiasm (OX) – from whence axons invade the suprachiasmatic nucleus (SCN) in the 
hypothalamus and where 1-10% RGC axons project ipsilaterally and 90-99% 
contralaterally into the optic tracts (OT) connecting with ventral lateral geniculate 
nucleus (VLGN) and dorsal lateral geniculate nucleus (DLN) in the thalamus; 
superior quadrigeminal brachium (SQB) running to the superior colliculus (SC) in the 
midbrain; IIIrd ventricle (IIIV).  (B)  Ventral light sheet fluorescent microscopic view of 
regenerated axon projections in an unsectioned mouse brain after ONC and 
pten/socs3 deletion.  Cholera toxin-B anterograde labelled regenerating RGC axons 
are seen in the transected ON and OX.  Note: (i), ectopic RGC axons regenerate 
centrifugally into each ON; (ii), overgrowth into the hypothalamus; and (iii), equal 
numbers of axons regenerating into each OT.  (C)  Lateral view of the 3D 
reconstruction showing axons regenerating into the diencephalon (inset shows low 
magnification of the whole brain following 3D reconstruction).  (D)  Quantification of 
RGC axon trajectories in 6 different mice (cases #1–6 - values = % total axons 
exiting the OX).  Note the following abnormalities: (i), near normal numbers of 
ipsilateral and contralateral RGC axons in the OT; and (ii), variable ectopic 
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regeneration of axons into the hypothalamus and contralateral ON (scale bar = 
200μm; from Luo et al., 2013 with permission). 
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